Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on chiral catalysis. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Discover a scalable, high-ee synthesis method for N-N axis chiral indole-pyrrole compounds. Ideal for chiral catalyst development with 97% ee and 62% yield. Reduce R&D costs and supply chain risks.
Discover how chiral phase transfer catalysis enables 92% ee and 80% yield in axial chiral isopyrone-indole synthesis for potent PC-3 tumor activity. Scale-ready for pharma R&D.
Discover scalable chiral indolinopyrrole synthesis with 99% ee and 90%+ yield. Ideal for oncology drug development. Reduce costs and supply chain risks.
Solve axial chiral synthesis challenges with high-yield, mild-condition process. Reduce R&D costs and supply chain risks for asymmetric catalysts.
Discover a novel indolocyclopentane synthesis method with >95% yield and 93% ee. Ideal for pharmaceutical R&D targeting PC-3 prostate cancer cells. Scale up with CDMO expertise.
Solve low yield & high cost in beta-nitroalcohol production. Our chiral copper catalysis achieves >95% yield, 96% ee, and green ethanol solvent. Scale to 100MT/yr.
Discover how this novel axial chiral phosphine catalyst enables high-yield, high-enantioselective synthesis for pharmaceutical intermediates, reducing production costs and supply chain risks.
Discover how chiral phosphoric acid catalysis enables high-yield, enantioselective synthesis of axial chiral aryl indoles for cancer drug development and supply chain de-risking.
Eliminate chiral column costs with novel crystallization-based resolution. Achieve >99% ee and 76-78% yield for 6,6'-dihydroxy-5,5'-bisquinoline. Scale to 100MT/yr with NINGBO INNO PHARMCHEM's CDMO expertise.
Discover high-purity axial chiral cyclopentenyl indole-naphthyl compounds with 99% ee for PC-3 cancer cell cytotoxicity. Optimize your drug development with scalable synthesis.
Discover how axial chiral bisindole catalysts with >95:5 er enable scalable asymmetric synthesis, reducing R&D costs and supply chain risks for pharmaceutical intermediates.
Discover how metal-free photoredox catalysis enables high-yield, enantioselective synthesis of chiral thiochroman-4-ketones for anticancer drug development. Reduce supply chain risks and GMP compliance costs.
Discover how metal-free photoredox catalysis enables high-yield, enantioselective synthesis of chiral chroman-4-ones for anticancer drug development. Reduce supply chain risks and improve purity.
Solve high-cost chiral synthesis challenges with this patent-validated method. Achieve >70% ee and 92% yield in mild conditions. Contact us for GMP-compliant production.
Discover how visible light-driven catalysis enables 80-90% yields with 90-99% ee for chiral alpha-unnatural amino acids, eliminating costly chiral resolution steps in drug development.
Discover a novel chiral tetrahydroindolocarbazole synthesis method with 92% yield and 95% ee. Eliminate harsh conditions and high costs in antitumor drug R&D. Contact us for scalable production.
Discover how this dual-chiral ligand enables 91% ee in asymmetric reactions, reducing R&D costs and supply chain risks for pharmaceutical intermediates.
Discover a novel chiral synthesis method for isopyrone-indole derivatives with 92% ee and 80% yield. Ideal for oncology drug development.
Discover efficient synthesis of axial chiral indole-naphthalene with >95% er, mild conditions, and scalable production. Reduce R&D costs and supply chain risks for asymmetric catalysis applications.
Solve your chiral synthesis challenges with this patent-validated method. Achieve >94% ee and 92% yield in mild conditions. Scale to 100 MT/yr with NINGBO INNO PHARMCHEM's CDMO expertise.